Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial.

Monika Gräser Oleg Gluz Claudia Biehl Daniel Ulbrich-Gebauer Matthias Christgen Jenci Palatty Sherko Kuemmel Eva-Maria Grischke Doris Augustin Michael Braun Jochem Potenberg Rachel Wuerstlein Katja Krauss Claudia Schumacher Helmut Forstbauer Toralf Reimer Andrea Stefek Hans Holger Fischer Enrico Pelz Christine Zu Eulenburg Ronald Ernest Kates Hua Ni Cornelia Kolberg-Liedtke Friedrich Feuerhake Hans Heinrich Kreipe Ulrike Nitz Nadia Harbeck

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Distinct gene signatures were associated with pCR vs iDFS in HER2+/HR- EBC. The potential role of IR in preventing recurrence suggests that patients with up-regulated IR signatures could be candidates for de-escalation concepts in HER2+ EBC.

Keyphrases

genome wide
epidermal growth factor receptor
rectal cancer
metastatic breast cancer
dna methylation
clinical trial
lymph node
study protocol
open label
phase iii
transcription factor
phase ii
real time pcr
free survival
placebo controlled
nucleic acid
double blind